Centiva Capital LP Has $384,000 Stock Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Centiva Capital LP lowered its stake in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 59.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,607 shares of the company's stock after selling 68,984 shares during the quarter. Centiva Capital LP's holdings in Bausch Health Companies were worth $384,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Sanders Morris Harris LLC lifted its position in shares of Bausch Health Companies by 16.0% during the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company's stock worth $234,000 after purchasing an additional 4,000 shares during the last quarter. Merit Financial Group LLC bought a new position in Bausch Health Companies in the 4th quarter worth approximately $228,000. SG Americas Securities LLC lifted its holdings in shares of Bausch Health Companies by 62.0% during the fourth quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock worth $26,614,000 after buying an additional 1,263,706 shares during the last quarter. DGS Capital Management LLC bought a new stake in shares of Bausch Health Companies in the fourth quarter valued at approximately $143,000. Finally, Tobam grew its stake in shares of Bausch Health Companies by 10.4% in the fourth quarter. Tobam now owns 15,034 shares of the company's stock worth $121,000 after acquiring an additional 1,422 shares during the last quarter. Institutional investors and hedge funds own 78.65% of the company's stock.

Bausch Health Companies Stock Performance

Shares of BHC stock traded up $0.06 during mid-day trading on Thursday, reaching $4.62. The company's stock had a trading volume of 1,341,007 shares, compared to its average volume of 2,617,599. The firm's 50-day moving average is $5.64 and its two-hundred day moving average is $7.03. The company has a market cap of $1.67 billion, a P/E ratio of -38.50, a PEG ratio of 0.37 and a beta of 0.34. Bausch Health Companies Inc. has a 1-year low of $3.96 and a 1-year high of $9.85.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). The business had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. Sell-side analysts anticipate that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on BHC shares. Jefferies Financial Group reiterated a "hold" rating and set a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. StockNews.com lowered shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Saturday, May 10th. Finally, Royal Bank of Canada boosted their price target on Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.